GSK grabs more diagnostics; FDA warns J&J's Bengay can cause burns; China studies psychotropics;

 @FiercePharma: Sanofi eyes emerging market buyouts beyond the BRICs. Article | Follow @FiercePharma

> GlaxoSmithKline ($GSK) has upped its position in companion diagnostics firm Response Genetics to 15.2%. Story 

> China has established China Academic Research Organization of Psychotropic (China AROP), to research psychotropic drugs as part of its development plan for the 2011-2015 period. Story 

> Australia-based Sirtex Medical reported a 27% increase in its U.S. sales of its radioembolization treatment for inoperable liver cancer in fiscal 2012 to $59 million. Release 

> In the report "Healthcare, Regulatory and Reimbursement Landscape - Mexico" analysts estimate that the pharmaceuticals market in Mexico will reach approximately $22.5 billion by 2020 at a projected CAGR of 7%. Release 

> Indian drugmaker Lupin has received FDA approval to make a generic version of Forest Laboratories' Lexapro. Story

Biotech News

 @FierceBiotech: Sanofi inks $163M tech pact to speed cancer drugs to clinic. News | Follow @FierceBiotech

 @JohnCFierce: 4SC spotlights partnership talks after liver cancer combo (with Nexavar) extends survival. More | Follow @JohnCFierce

 @RyanMFierce: Viehbacher reminded folks in China that Sanofi sees good emerging market opportunities beyond BRIC countries. More | Follow @RyanMFierce

> GW Pharma IDs promising epilepsy drug in cannabis. Report

> General Dynamics lands a $42M DoD drug development contract. News

> Sanofi snags FDA OK for oral MS drug Aubagio, prices at $45K. News

Medical Device News

 @FierceMedDev: Asia isn't the only growth market: KCI is expanding in Brazil. Release | Follow @FierceMedDev

 @MarkHFierce: Covidien is closing a SC plant and slashing nearly 600 full time and contract jobs. Story | Follow @MarkHFierce

 @DamianFierce: A St. Jude exec says the device tax wasn't the sole cause of the company's job cuts and restructuring. Item | Follow @DamianFierce

> J&J/Ethicon invests $185M in surgical suture plant expansion. Article

> iWalk pulls in $17M for bionic limbs. News

> Study: Dune's MarginProbe cuts down on repeat cancer surgery. More

Pharma Manufacturing News

> Endo recalls potentially 'super potent' painkillers. News

> Sartorius opens $23M bioreactor plant. More

> Canada issues new ranking system for plant violators. Story

> Pfizer injects cloud computing into complex supply chain. Article

Vaccines News

> Potential allergy cure is just under the skin. Article

> HHS awards flu antigen contract to CSL. News

> WHO injects Prevnar 13 with adult prequalification status. More

> Sanofi's dengue vaccine falters in clinical trial. Story

And Finally... Bengay from Johnson & Johnson ($JNJ) and Icy Hot from Sanofi ($SNY) have been tied to 43 reports of burns, mostly second and third degree, the FDA reports today. Story

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.